BioStock: Pila Pharma broadens XEN-D0501 with new indication

During spring, Malmö-based Pila Pharma announced that they had applied for orphan drug designation for the drug candidate XEN-D0501 for the treatment of erythromelalgia. In mid-July, the company announced that the FDA had given the application the green light and with previous clinical findings as a base, the project can go straight into clinical phase II/III studies. BioStock contacted Pila Pharma’s CEO Dorte X. Gram to find out more about what the summer’s big news means for the company.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/08/pila-pharma-broadens-xen-d0501-with-new-indication/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se